Acousia Completes Patient Enrollment for Cisplatin Ototoxicity Prevention Study
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
Sensorion was recommended to continue the study of a drug candidate for the prevention of Cisplatin-Induced Ototoxicity (CIO).